Immediate antiretroviral therapy in young HIV-infected children: benefits and risks

Intira J. Collins, Ali Judd, and Diana M. Gibb

Purpose of review
Recent WHO guidelines recommend immediate initiation of lifelong antiretroviral therapy (ART) in all children below 5 years, irrespective of immune/clinical status, to improve access to paediatric ART. Interim trial results provide strong evidence for immediate ART during infancy because of high short-term risk of mortality and disease progression, but there is wider debate regarding the potential risks and benefits of immediate ART in asymptomatic children aged above 1 year. Concerns include long-term toxicities and treatment failure, particularly in resource-constrained settings with limited paediatric treatment options.

Recent findings
Benefits of immediate ART among infants appear to be maintained in the mid-term to long-term, with low risk of treatment failure, and better neurodevelopmental outcomes. In contrast, a trial reported no benefits of immediate versus deferred ART in asymptomatic children aged above 1 year. However, observational studies suggest that ART initiation at older ages and lower CD4 reduces the probability of immune reconstitution, with unclear implications on risk of clinical events or treatment change. A recent trial on treatment interruption following early intensive ART suggest that this may be a safe alternative approach.

Summary
Although there are clear benefits of immediate ART among infants, there remains conflicting evidence on the benefits for older children.

Keywords
antiretroviral therapy, children, immune response, neurodevelopment, survival

INTRODUCTION
In 2011, an estimated 3.3 million children aged below 15 years were living with HIV, of whom more than 90% lived in sub-Saharan Africa, and the vast majority were infected through mother-to-child transmission [1]. Despite the rapid scale up of interventions for prevention of mother-to-child transmission of HIV, coverage in the top 21 Global Plan priority countries remains highly variable, ranging from 9% to more than 95% [2]. Within these priority countries, there were an estimated 210,000 children newly infected in 2012 alone [3]. Without antiretroviral therapy (ART), up to 50% of children will die by 2 years of age in resource-limited settings [4,5]. Yet, the global coverage of ART among children continues to lag behind at 28% of those in need of treatment, as compared to 58% in adults [6].

The WHO recommendations on when to start ART in children have been revised four times over the past decade, each time relaxing the eligibility criteria to higher CD4 levels, and more recently increasing the age for immediate ART from all those below 2 years to all below 5 years, irrespective of clinical or immune status [7] (Table 1) [7–11]. Older children are recommended to start ART when CD4 is less than 500 cells (an increase from <350 cells), in alignment with adult guidelines, and following studies which showed similar risk of disease progression in children aged above 5 years as young adults [12].

In contrast, the United States and European Paediatric European Network for Treatment of AIDS (PENTA) paediatric guidelines only recommend immediate ART for all infants below 12 months,
Does antiretroviral treatment at high CD4 counts reduce disease risk for HIV-positive patients?

**KEY POINTS**

- Strong evidence of benefits of immediate lifelong ART in infants in mid-term to long-term AIDS-free survival, with good response to therapy, and benefits in some neurodevelopmental outcomes.
- Conflicting evidence of benefit of immediate ART in children aged above 1 year: a clinical trial reported no benefit while observational data suggest benefit for long-term immune reconstitution.
- Treatment-sparing strategies including early intensive ART in infancy followed by treatment interruption, to minimize long-term toxicity and risk of drug resistance, appears to be safe in children but requires close monitoring.

whereas older children are recommended to initiate ART based on clinical and immune status [13,14].

However, the WHO recommendations are based on a public health approach, taking into account programmatic issues in resource-limited settings, such as difficulties in provision of CD4 testing and high rates of loss-to-follow-up among children not eligible for treatment [15,16,17]. Furthermore, recent data suggest that a large number of children still present late for treatment, when severely immunocompromised and at advanced disease stage [18], with high risk of mortality during screening and in the first year of ART [15], especially in those aged below 2 years [19,20].

With the aim to minimize the risk of disease progression and mortality, under the consolidated WHO guidelines HIV-infected children would initiate lifelong ART from infancy. In this review, we focus on the most recent evidence on the risks and benefits of earlier initiation of ART in three main areas: survival and AIDS-free survival; immune restoration, as this is closely associated with risk of disease progression; and neurodevelopmental outcomes, because of their important implications on quality of life. Lastly, we briefly review the latest evidence on treatment-sparing strategies. This is critical to minimize long-term toxicities and to preserve future treatment options, particularly in resource-limited settings wherein often only first and second-line regimens are available [21].

**WHEN TO START ANTIRETROVIRAL THERAPY: SURVIVAL AND AIDS-FREE SURVIVAL**

Up until 2008, the WHO recommendations on when to initiate ART in children were largely based on observational data which demonstrated younger age and poorer immune status as the main predictors of risk of disease progression and death, as well as higher risk in untreated children in sub-Saharan Africa compared with Europe and the USA [22,23]. To date, there have only been two clinical trials assessing when to start ART in children, both conducted in low or middle-income countries.

The Children with HIV early antiretroviral therapy (CHER) trial in South Africa randomized 377 asymptomatic HIV-infected infants (CD4 > 25% at median 7 weeks of age) to immediate initiation of ART before 12 weeks of age or deferred ART based on WHO 2006 clinical or CD4 criteria. After a median of only 40 weeks, there was a 76% [95% confidence interval (CI), 49–89%, \( P < 0.001 \)] reduction in mortality and 75% reduction in disease progression (95% CI, 59–85%, \( P < 0.001 \)) in the early treatment arm [24], and these results were confirmed in the final analysis at 4 years of follow-up [25**] (Table 2) [25**,26,27,28**,29*].

**Table 1.** Changes in World Health Organization recommendations on immunological threshold of when to start antiretroviral therapy by age from 2003 to 2013

<table>
<thead>
<tr>
<th>Age</th>
<th>&lt;12 months</th>
<th>12–23 months</th>
<th>24–35 months</th>
<th>36–59 months</th>
<th>≥60 months</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WHO guidelines</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2003 [8]</td>
<td>CD4%</td>
<td>&lt;20%</td>
<td>&lt;15%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Absolute CD4</td>
<td>NA</td>
<td>NA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2006 [9]</td>
<td>CD4%</td>
<td>&lt;25%</td>
<td>&lt;20%</td>
<td>&lt;15%</td>
<td>&lt;15%</td>
</tr>
<tr>
<td></td>
<td>Absolute CD4</td>
<td>&lt;1500 cells/mm(^3)</td>
<td>&lt;750 cells/mm(^3)</td>
<td>&lt;350 cells/mm(^3)</td>
<td>&lt;200 cells/mm(^3)</td>
</tr>
<tr>
<td>2008 [10]</td>
<td>CD4%</td>
<td>All</td>
<td>&lt;20%</td>
<td>&lt;15%</td>
<td>&lt;20%</td>
</tr>
<tr>
<td></td>
<td>Absolute CD4</td>
<td>All</td>
<td>&lt;750 cells/mm(^3)</td>
<td>&lt;350 cells/mm(^3)</td>
<td>&lt;200 cells/mm(^3)</td>
</tr>
<tr>
<td>2010 [11]</td>
<td>CD4%</td>
<td>All</td>
<td>All</td>
<td>&lt;25%</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Absolute CD4</td>
<td>All</td>
<td>All</td>
<td>&lt;750 cells/mm(^3)</td>
<td>≤350 cells/mm(^3)</td>
</tr>
<tr>
<td>2013 [7]</td>
<td>CD4%</td>
<td>All</td>
<td>All</td>
<td>All</td>
<td>All</td>
</tr>
<tr>
<td></td>
<td>Absolute CD4</td>
<td>All</td>
<td>All</td>
<td>All</td>
<td>All</td>
</tr>
</tbody>
</table>
Table 2. Summary of recent trials on in HIV-infected children

<table>
<thead>
<tr>
<th>Study and setting</th>
<th>Population</th>
<th>Methods</th>
<th>Results</th>
<th>Summary and comment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CHER trial, South Africa (a)</strong>&lt;br&gt;Interim analysis [26]</td>
<td>HIV-infected asymptomatic infants aged 6–12 weeks with CD4 &gt;25%</td>
<td>377 children randomized to deferred ART based on CD4/clinical criteria (Def-ART, n = 125); immediate ART (early-ART, n = 252); primary outcome: death or treatment failure [immunological, virological or clinical]</td>
<td>At randomization, median age and CD4% was 7.4 weeks and 33%; at 40 weeks, 76% reduction in death and 75% reduction in disease progression to CDC severe stage B or stage C event in the early-ART arm (P &lt; 0.001); enrolment in the Def-ART arm was stopped after the interim analysis</td>
<td>Results led to change in international guidelines to recommend immediate ART in infants</td>
</tr>
<tr>
<td>(b) Neurocognitive sub-study [27*]</td>
<td>As above, with additional HEU and HU controls</td>
<td>Cross-sectional sub-study; examination using GMDS</td>
<td>90 HIV-infected children (63 early-ART and 26 Def-ART), 155 HEU and 164 HU controls were included; median age of 11 months; significantly lower general and locomotor scores in the Def-ART versus; early-ART arm; children in early-ART arm had similar scores to HIV-uninfected controls except for locomotor score</td>
<td>Early ART was associated with better neurological outcomes at 11 months; cross-sectional design, so unclear if the outcome changes over time on ART; children in the Def-ART arm had higher incidence of illness and hospitalization, which may have contributed to their poorer outcome</td>
</tr>
<tr>
<td><strong>PREDICT study, Cambodia and Thailand (a)</strong> Final analysis [28**]</td>
<td>HIV-infected children aged 1–12 years with CD4 of 15–24% and no history of AIDS illness</td>
<td>Children randomized to deferred ART based on CD4/clinical criteria (Def-ART, n = 150); immediate ART (early-ART, n = 150); primary outcome: AIDS-free survival</td>
<td>Median follow-up was 4.8 years, 9% lost to follow-up; overall mortality was 16.8% in the Def-ART arm and 9% in the early ART arm; 38% of children in the Def-ART arm, 25% in ART-40 weeks, and 21% in ART-96 weeks group reached the primary endpoint (P = 0.02); time to reintroduction of ART was 33 weeks (IQR, 26–45) in the ART-40 weeks and 70 weeks (53–109) in ART-96 weeks arm; at end of the trial, 19 and 32% of patients remained off ART, respectively; very few children switched to second-line across all arms</td>
<td>Long-term survival benefit of early ART as compared to deferred ART, with good long-term outcomes despite TI; early time-limited ART appears to be a safe strategy but requires close clinical and CD4 monitoring; there was no early continuous ART arm with which to compare the outcomes of the two TI arms; insufficient power to detect difference in outcomes between the two TI arms</td>
</tr>
</tbody>
</table>
The majority of excess deaths observed in the deferred treatment arm was among untreated children who died before meeting the clinical/immune criteria for ART. Following the interim result of this trial, the WHO, United States and PENTA guidelines were all revised in 2008 to recommend immediate ART in all HIV-infected infants under 12 months, irrespective of clinical or immune status [10]. In the WHO 2010 guidelines, this was extended to all children under 24 months [11], for programmatic reasons and also in recognizing that observational data indicate the higher risk of AIDS and death extend to young children below 2 years [22,23]. Importantly, final results of the CHER trial showed that very few children in the early ART arms switched to second line (4 of 252), although this may have been partly because of the treatment-sparing strategy in which infants on early ART were randomized to treatment interruption after 40 or 96 weeks of ART (see later section) [25**].

The Paediatric Randomized Early vs. Deferred Initiation in Cambodia and Thailand (PREDICT) study, randomized 284 children, aged 1–12 years with CD4 of 15–24% and no AIDS-defining illness to immediate ART or deferred treatment until CD4 less than 15% or Centres for Disease Control and Prevention (CDC) stage C. At 3 years of follow-up, there was no difference in the AIDS-free survival: 97.9% (95% CI, 93.7–99.3) and 98.7% (95% CI, 94.7–99.7, \( P = 0.6 \)) in the early and deferred arms, respectively [28**]. The rate of events was very low (one death and five CDC C events), and the authors concluded that the study was underpowered to detect a difference between the two strategies. However, there were also no differences between the two arms in any secondary outcomes: rate of hospitalization, CDC stage B or C events, virological suppression, immunological response or neurodevelopmental outcomes, suggesting no significant benefit of earlier treatment in asymptomatic children above 1 year. However, it is important to note that children in the deferred treatment arm received CD4 assessments every 3 months and prompt ART initiation at higher median CD4% as compared to other studies in comparable routine care settings [30,31]. Furthermore, this trial included mainly older surviving children, with a median age of 6.4 years at randomization (only 26% were aged <3 years and 6% aged 1–2 years); therefore, the findings may not be generalizable to all children below 5 years.

In the absence of clinical trial data, the South Africa International Epidemiologic Database to Evaluate AIDS collaboration conducted a causal modelling analysis, using data from their large cohort of approximately 3000 children aged 2 to
below 5 years at first presentation [32*]. The model estimated mortality over 3 years if the 2013 guidelines for immediate ART was implemented as compared to starting ART when CD4 declined to less than 25% or less than 750 cell counts as per routine practice within the cohort. The model showed no significant benefit in mortality from the immediate treatment strategy, most likely because of the relatively low risk of mortality in children aged 2–5 years with CD4 more than 25%.

In summary, there is limited evidence to support immediate ART in children aged 2–5 years in terms of survival or AIDS-free survival. This is partly reflected in the WHO recommendations, which state that priority for immediate ART should be given to children aged less than 2 years or those aged 2–5 years with advanced disease stage [7].

IMMUNOLOGICAL RECONSTITUTION

As most children on ART are now surviving into adolescence and young adulthood, there is a need to study the impact of earlier treatment initiation on long-term response and morbidity. Numerous studies have shown that children who initiate ART at low CD4 or older age are less likely to achieve immune reconstitution to near normal levels, often defined as CD4 at least 25% [33–35] or at least 30% [36], which represents the upper threshold for start of treatment in children above 2 years. Children who fail to reach this threshold may be vulnerable to disease progression. However, most studies have been limited to follow-up of 2–5 years on ART, and the long-term trajectory of immune response is unclear.

To address that, one novel study by Lewis et al. [37**] used data from the PENTA-5 clinical trial, of 127 European/South American children in an immunological sub-study, to model the CD4 trajectories of children on ART into adulthood. As expected, the long-term CD4 z-scores were significantly lower for children starting ART at older ages and those with lower pre-ART CD4. However, children starting with lower CD4 cell count at younger ages had greater capacity for immune reconstitution as compared to older children, possibly due to increased thymic activity and a shorter duration of infection [37**]. The same model was also applied to data from the Antiretroviral research for Watoto (ARROW) trial, of 1206 children randomized to clinical-based or clinical and laboratory-based monitoring in Uganda and Zimbabwe, with 4 years of follow-up on ART [38*]. Similar results were observed, whereby higher long-term CD4 cell counts were predicted for children starting ART at younger ages and with higher CD4 cell counts (P < 0.0001). Interestingly, children starting ART aged above 10 years were unlikely to ever normalize CD4 cell counts, irrespective of their CD4 at start of therapy.

These findings are consistent with recent results from an observational study in Thailand. Among 507 children followed up for a median of 7 years, 22% failed to achieve immune reconstitution defined as confirmed CD4 of at least 25%, of whom over half had sustained viral suppression less than 400 copies throughout their follow-up time [39]. Age above 7 years and very low CD4 less than 5% at start of ART were associated with poor immune reconstitution, although the impact on clinical events was not assessed. In contrast, in the PREDICT trial, composed of similarly older children, there were no differences in long-term immune response in the immediate versus deferred ART arms, and it was unclear if there was an effect of age at start of therapy [28**].

In summary, observational studies suggest that delayed initiation of ART until age above 7 years or when severely immunosuppressed significantly reduces the probability of immune reconstitution, although the clinical implications of this remains unclear. In adult studies, nonimmune response despite viral suppression has been associated with increased risk of severe clinical events [40] and death [41], whereas prolonged periods of immune reconstitution (defined as CD4 ≥ 500 cells/mm³) have been associated with improved life expectancy, comparable to the general population [42,43]. No equivalent study has yet been conducted in perinatally infected patients, mainly because of lack of data on long-term clinical outcomes; this highlights the need for continued follow-up after children transfer to adolescent and adult clinics.

NEURODEVELOPMENTAL OUTCOMES

There were two recent reviews on neurodevelopmental outcomes in perinatally HIV-infected children and adolescents [44**,45]. AIDS-defining illness and low CD4 have been associated with poorer neurodevelopmental outcomes in resource-rich and resource-limited settings [46*,47]. However, the debate on whether earlier treatment initiation improves neurodevelopmental outcomes among children without advanced disease stage continues. In the CHER trial’s neurological sub-study, children in the early ART group had significantly higher General and Locomotor scores at 11 months of age as compared to the deferred ART group, and were comparable to HIV-uninfected controls [27]. However, differences between the groups were relatively small, and the mean General and
Does antiretroviral treatment at high CD4 counts reduce disease risk for HIV-positive patients?

Locomotor score in the deferred arm remained within the normal developmental range.

In the PREDICT trial sub-study, with a median age 9 years at last examination, there was no difference in the neurocognitive performance in the early versus deferred ART groups, despite repeat measurements throughout the study. Both groups had poorer outcomes as compared to HIV-exposed uninfected controls on key measures [29]. However, it is important to note that these measures were based on the methods developed in the USA or Europe and have not been standardized for these other settings. Also comparisons with HIV-exposed uninfected controls may be subject to unmeasured confounders, such as differences in the family settings and access to care, which may affect outcomes. Also the magnitude of differences in outcomes and their impact on daily function, learning capabilities and quality of life are unknown.

OTHER CONSIDERATIONS: TOXICITIES, VIROLOGIC FAILURE AND TREATMENT-SPARING STRATEGIES

As with adults, earlier initiation of lifelong ART poses potential risks of long-term toxicities, increased risk of virological failure and limited treatment options. A fuller discussion of potential toxicities is beyond the scope of this review. Briefly, concerns have been raised regarding prolonged exposure to tenofovir (recommended first line for children >3 years) and protease inhibitors (lopinavir is recommended first line for children <3 years) among children and adolescents because of their impact on bone mineral density/kidney function and metabolic disease respectively, during critical periods of growth and development [48,49,50]. Such concerns are particularly important in resource-constrained settings wherein there is limited monitoring of such toxicities.

Recent results from the CHER and PREDICT trials show very good long-term virological suppression and low rates of switch to second line among children on immediate ART [25,26]. However, data from observational studies in routine care settings suggest much higher rates of virological failure in Asia and Africa (range from 19 to 25% at 3–5 years of ART in settings with routine virological monitoring) [51,52,53]. Also a recent meta-analysis reported higher levels of triple-class virological failure in European adolescents starting ART compared with 5–9-year olds [54]. In countries, where only first line and second-line treatment options are available, this presents a critical dilemma and has resulted in trials exploring treatment-sparing strategies.

The first is the Nevirapine Resistance Study (NEVEREST) trial, wherein children aged below 3 years started ART with lopinavir-based therapy and continued on this regimen or switched to nevirapine-based regimen after a prolonged period of virological suppression with the aim of preserving lopinavir for second line. Results suggested that those who switched to nevirapine had poorer virological outcomes but better growth and CD4 responses [55]. The other strategy was within the CHER trial, in which children on early ART had a treatment interruption at 40 or 96 weeks with CD4 and clinical-guided criteria for reinitiation of ART [25]. Up to a third of children in the 96 weeks arm remained off treatment at the end of the study with good CD4 profiles. The study showed that this strategy was well tolerated and superior when compared with deferred ART. However, the study was not powered to detect a difference in outcomes between the two treatment interruption arms, and there was no early ART continuous arm to compare with. These findings suggest that there may be a future role for early intensive treatment followed by periods of interruption, but, critically, rely on close clinical and laboratory monitoring, which is not available everywhere. Nonetheless, the findings confirm conclusions from previous studies that, unlike in adults, treatment interruption in children appears well tolerated without higher risk of mortality, serious clinical events [56] or negative impact on long-term immune/virological response after reinitiation of ART [57], although further study is needed.

CONCLUSION

With an estimated 300,000 children newly infected with HIV in 2012 alone, questions concerning when to start lifelong ART remain extremely relevant to paediatrics. Although there is strong evidence of wide ranging benefits of immediate ART in infants, there remains conflicting evidence on the benefits of early ART in asymptomatic children above 1 year. Modelling studies suggest that delayed ART initiation at older ages and lower CD4 reduces the probability of immune reconstitution with unknown implications for long-term disease progression, highlighting the need for continued follow-up of perinatally infected patients as they transfer to adolescent and adult clinics. Lastly, recent trial results suggest that treatment interruption following early intensive ART during infancy may be a well tolerated alternative strategy but requires close monitoring, which is not available in most of the affected regions.
REFERENCES AND RECOMMENDED READING

Papers of particular interest, published within the annual period of review, have been highlighted as:

■ of special interest
■ of outstanding interest


6. A large pooled analysis of over 12,000 children, which showed poorer survival in perinatally infected as compared to postnatally infected children without ART.


Does antiretroviral treatment at high CD4 counts reduce disease risk for HIV-positive patients?


45. Insightful review of studies on neurodevelopment in HIV-infected children and adolescents in randomized trials and observational studies.


48. Cross-sectional study showed that HIV-infected ART-naive children in Uganda with CD4 more than 350 cells had poorer neurocognitive and motor scores as compared to uninfected controls despite having high CD4 (median >655 cells).


50. Cross-sectional study of HIV-infected youth (aged 7–16 years) in the USA, showed children with previous CDC C event had poorer cognitive performance, whereas children without CDC C events performed comparably to HIV-uninfected controls.


52. Comprehensive review of long-term treatment complications and toxicities of children and adolescents on ART as part of a special issue on perinatally HIV-infected adolescents.


54. Insightful review of studies on neurodevelopment in HIV-infected children and adolescents in randomized trials and observational studies.